Latest News

Aroa Biosurgery opens new pathway for advanced wound treatment amidst COVID-19 disruption in the United States31 Mar 2020

San Diego, U.S. Soft tissue repair company Aroa Biosurgery is stepping up to support clinicians and their patients who are battling to treat wounds amid disruption to many existing U.S. facilities for wound care due to COVID-19.

Aroa Vice President Commercial, Brad Adams says the company has opened an additional pathway for its clinicians and patients to maintain access to Endoform®, an extracellular matrix technology that is proven to help wounds heal faster.

Continue Reading

COVID-19 Update – Aroa Biosurgery is well placed to maintain supply of Endoform® and Myriad™ products to clinicians and patients19 Mar 2020

Aroa Biosurgery is taking the appropriate precautions and measures amid a rapidly changing global picture for COVID-19 virus.

CEO Brian Ward said; “We extend our thoughts to everyone affected by COVID-19. Our priority is ensuring our employees, contractors and customers are safe and protected from the spread of the virus. We will continue to make any necessary changes, and monitor the potential impacts of COVID-19 on our employees, customers and overall business, daily. At this stage we are not experiencing significant disruption or impact to the underlying production and marketing operations of our business and we continue to have adequate stock levels in market.”

Continue Reading

Aroa Biosurgery expands options for soft tissue repair with launch of Myriad™20 Feb 2020

Auckland, NZ. Aroa Biosurgery, the Auckland-based privately held soft-tissue repair company, has launched Myriad™, a new product for soft tissue repair and reconstruction, in the United States market.

Aroa Chief Executive, Brian Ward says the product name, Myriad™, reflects the multitude of potential uses for this product in soft tissue repair and reconstruction.

Continue Reading
1234567Next ›